Key result
Targeting systolic blood pressure <120 mm Hg in patients at high cardiovascular risk resulted in lower rates of cardiovascular events and mortality compared with standard treatment (<140 mm Hg).
Why the study?
Does targeting systolic blood pressure <120 mm Hg reduce cardiovascular events and mortality in patients at high cardiovascular risk?
Does targeting systolic blood pressure <120 mm Hg reduce cardiovascular events and mortality in patients at high cardiovascular risk?
The SPRINT trial demonstrated that intensive blood pressure lowering (SBP <120 mm Hg) reduces cardiovascular events and mortality in high-risk patients, prompting updates to hypertension guidelines.
ome physicians may be nostalgic for the years 2011 to 2015, back when most hypertension guidelines agreed to use a threshold of 140/90 mm Hg to define hypertension, to initiate drug treatment, and as a treatment target in the majority of adult patients (except in elderly adults, for whom higher values were tolerated).Since then, one of the most-if not the most-important trial in the field of hypertension, SPRINT (Systolic Blood Pressure Intervention Trial), showed that targeting systolic blood pressure (SBP) <120 mm Hg in patients at high cardiovascular risk resulted in lower rates of cardiovascular events and mortality compared with standard treatment (<140 mm Hg), and led scientific societies to reconsider guidelines.
No takes yet. Share an insight, caveat, or question.
Emmanuelle Vidal‐Petiot (2022) conducted a review in Hypertension. Targeting systolic blood pressure <120 mm Hg vs. Standard treatment (<140 mm Hg) was evaluated on Cardiovascular events and mortality. Targeting systolic blood pressure <120 mm Hg in patients at high cardiovascular risk resulted in lower rates of cardiovascular events and mortality compared with standard treatment (<140 mm Hg).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: